Ellington Management Group’s Ocular Therapeutix OCUL Stock Holding History

Ellington Management Group’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,100	Closed	-$131K	–	740
2018 Q1	$131K	Buy	+20,100	New	+$113K	0.01%	770
2017 Q2	–	Sell	-12,200	Closed	-$113K	–	829
2017 Q1	$113K	Sell	12,200 -9,000	-42%	-$75K	﹤0.01%	637
2016 Q4	$177K	Buy	21,200 +4,300	+25%	+$33.4K	0.03%	462
2016 Q3	$116K	Buy	16,900 +5,900	+54%	+$36K	0.03%	601
2016 Q2	$54K	Buy	+11,000	New	+$109K	0.08%	239
2015 Q3	–	Sell	-28,068	Closed	-$590K	–	836
2015 Q2	$590K	Buy	28,068 +21,068	+301%	+$522K	0.14%	196
2015 Q1	$294K	Buy	+7,000	New	+$230K	0.06%	469

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Ellington Management Group's OCUL Position: Q2 2018 in Review

Ellington Management Group sold out of Ocular Therapeutix (OCUL) in Q2 2018, closing a stake of 20,100 shares — an estimated $131K sold.

Ellington Management Group first reported a position in OCUL in Q1 2015 and held it in 7 quarters. The position peaked at $590K in Q2 2015. 68 funds tracked by Wall St. Rank hold OCUL as of Q2 2018.

Ellington Management Group reported no remaining Ocular Therapeutix position as of Q2 2018 after selling out during the quarter.
Ellington Management Group sold 20,100 Ocular Therapeutix shares in Q2 2018, an estimated $131K.
Ellington Management Group first reported a position in Ocular Therapeutix in Q1 2015 and held it in 7 quarters.
Ellington Management Group's Ocular Therapeutix position peaked at $590K in Q2 2015.
68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.